StoryCommercial
Tempus signs USD 200M deal with AstraZeneca and Pathos to build an oncology foundation model on its data
Tempus AIxT CDx genomic profiling
Tempus agreed multi-year deals with AstraZeneca and Pathos AI to build a large AI model of cancer from Tempus's de-identified clinical and molecular data. Tempus receives USD 200M in data-licensing and model fees, and all three companies will share the finished model for drug discovery.
- USD 200M in data-licensing and model-development fees to Tempus.
- Model trained on Tempus's de-identified oncology data, combining several data types.
- Builds on a Tempus-AstraZeneca partnership first announced in 2021.